Molecular structure of Lidocaine, CAS Number: 137-58-6
Lidocaine (CAS 137-58-6)
Application:
Lidocaine is a selective inverse peripheral histamine H1-receptor agonist
CAS Number:
137-58-6
Purity:
≥98%
Molecular Weight:
234.34
Molecular Formula:
C14H22N2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lidocaine is a synthetic organic compound characterized by its amide structure, primarily composed of an aromatic ring linked to an aminoethyl chain. It is a white, crystalline powder that is soluble in alcohol, ether, and benzene. In the research applications, it serves as a standard agent in studies exploring the mechanisms of sodium channel function due to its ability to bind to specific sites within these channels. Lidocaine in electrophysiological experiments are used to understand the gating properties of sodium channels and to map their role in the generation and conduction of electrical signals in various cell types. The compound′s impact on these ion channels has made it a subject of interest in the field of neurobiology, where it is used to elucidate the fundamental processes underlying neuronal excitability and conduction.
Lidocaine (CAS 137-58-6) References
- Effect of lidocaine on the early inward transient current in sheep cardiac Purkinje fibers. | Weld, FM. and Bigger, JT. 1975. Circ Res. 37: 630-9. PMID: 1192560
- Molecular action of lidocaine on the voltage sensors of sodium channels. | Sheets, MF. and Hanck, DA. 2003. J Gen Physiol. 121: 163-75. PMID: 12566542
- Rate-dependent effects of lidocaine on His-Purkinje conduction in the intact neonatal heart--characterization and amplification by N-acetylprocainamide. | Dise, TL., et al. 1991. J Pharmacol Exp Ther. 259: 535-42. PMID: 1719192
- Adverse effect of lignocaine (lidocaine) on skin destined for keratinocyte culture. | Mountford, EM., et al. 1991. J Invest Dermatol. 97: 746. PMID: 1940449
- Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures. | van den Broek, MP., et al. 2011. Clin Pharmacokinet. 50: 461-9. PMID: 21651313
- Adverse effect of lignocaine (Lidocaine) on skin destined for tissue culture. | Payne, CM., et al. 1990. J Invest Dermatol. 94: 153. PMID: 2295832
- Plasma lignocaine levels during transurethral prostatectomy. | Eardley, I., et al. 1989. Ann R Coll Surg Engl. 71: 278-80. PMID: 2802473
- Direct detection of glucuronide metabolites of lidocaine in sheep urine. | Doran, GS., et al. 2018. J Chromatogr B Analyt Technol Biomed Life Sci. 1076: 84-90. PMID: 29406032
- The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders. | Berk, T. and Silberstein, SD. 2018. Headache. 58: 783-789. PMID: 29536530
- Chemical stability of lignocaine (lidocaine) and adrenalin (epinephrine) in pH-adjusted parenteral solutions. | Bonhomme, L., et al. 1988. J Clin Pharm Ther. 13: 257-61. PMID: 3235475
- The Effect of Lidocaine and Bosutinib on 4T1 Murine Breast Cancer Cell Behaviour In Vitro. | Wall, TP., et al. 2021. Anticancer Res. 41: 2835-2840. PMID: 34083273
- OCT2013, an ischaemia-activated antiarrhythmic prodrug, devoid of the systemic side effects of lidocaine. | Hesketh, LM., et al. 2022. Br J Pharmacol. 179: 2037-2053. PMID: 34855992
- A recirculatory model of the pulmonary uptake and pharmacokinetics of lidocaine based on analysis of arterial and mixed venous data from dogs. | Krejcie, TC., et al. 1997. J Pharmacokinet Biopharm. 25: 169-90. PMID: 9408858
Inhibitor of:
ACCN5, AChRα9, Annexin IV, ASIC-β, ASIC1, ASIC4, CNG-1β, CNG-4, CNGA2, connexin 36, GlyR α3, GPD1L, Histamine H1 Receptor, Histatin 2, Junctional SR Marker, KCNE3, LYPD5, MrgA4, MrgB4, MRGF, Muted, Na+ CP type Iβ, Na+ CP type IIIα, Na+ CP type IIIβ, Na+ CP type IVα, Na+ CP type VIIα, NaS-1, Neurofascin, Neuron navigator 1, NHEDC1, Obp1a, OCT, ODR4, Olfr1044, Olfr1058, Olfr1098, Olfr1104, Olfr319, Olfr320, Olfr325, Olfr33, Olfr342, Olfr345, Olfr347, Olfr348, Olfr351, Olfr354, Olfr356, Olfr358, Olfr371, Olfr376, Olfr395, Olfr639, Olfr66, Olfr661, Olfr663, Olfr665, Olfr667, Olfr724, Olfr725, Olfr726, Olfr727, Olfr728, Olfr739, Olfr74, Olfr781, Olfr782, Olfr784, Olfr851, Olfr853, Olfr854, Olfr857, Olfr862, Olfr866, Olfr867, Olfr868, Olr34, OR10AG1, OR1J1, OR1L8, OR2AP1, OR2D2, OR2J2, OR2T3, OR2V1, OR2W3, OR4D9, OR4E2, OR52E5, OR5H14, OR5H15, OR5K2, OR5V1, OR6C1, OR6C6, OR6C68, OR6C74, OR6C76, OR9A2, OTOP1, PLU-1, Prestin, RTP4, SCNM1, SLAM, SLC10A4, Slc22a22, SLC41A2, sodium channel type I, sodium channel type II, sodium channel type III, sodium channel type IV, Staphylococcus aureus TSST-1, T2R13, T2R26, T2R8, TASK-3, THEM92, TMC2, TREK-2, TRPV3, V1RB4, V1RB5, V1RH1, Vmn1r129, Vmn1r31, Vmn2r103, Vmn2r2, Vmn2r20, Vmn2r4, Vmn2r77, Vmn2r79, and Vmn2r90.Activator of:
ASIC2, CES1, MIPEP, MrgA3, MrgB13, MrgB4, MrgB5, MrgB8, MrgH, Mrgprh, MRGX1, MRGX4, Na+ CP type IVα, Na+ CP type XIα, Olfr107, Olfr1104, OTOP3, PIEZO1, TMC1, and TorsinB.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lidocaine, 50 mg | sc-204056 | 50 mg | $50.00 | |||
Lidocaine, 1 g | sc-204056A | 1 g | $128.00 |